Beigene

Beigene CROIC

The Cash Return on Invested Capital (CROIC) of Beigene (6160.HK) as of Nov 7, 2026 is 17.93 %. In the previous year, Cash Return on Invested Capital (CROIC) was -15.47 % — a change of -215.90% (higher).

CROIC

17.93 %

YoY

-215.90%

Last updated:

Cash Return on Invested Capital (CROIC) of Beigene is 2025 17.93 % . Cash Return on Invested Capital (CROIC) of Beigene was 2024 -15.47 % . It decreases by -215.90% higher compared to the previous year.

The Beigene CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-38.31 USD
Jan 1, 2019
-83.76 USD
Jan 1, 2020
-21.69 USD
Jan 1, 2021
-23.74 USD
Jan 1, 2022
-40.01 USD
Jan 1, 2023
-40.04 USD
Jan 1, 2024
-15.47 USD
Jan 1, 2025
17.93 USD
The Beigene CROIC history
YEARCROICYoY
17.93 %-215.90%
-15.47 %-61.36%
-40.04 %+0.07%
-40.01 %+68.55%
-23.74 %+9.42%
-21.69 %-74.10%
-83.76 %+118.61%
-38.31 %+477.90%
-6.63 %-79.30%
-32.02 %-161.82%
51.81 %-244.59%
-35.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beigene stock

Cash Return on Invested Capital (CROIC) of Beigene is 17.93 % in 2025.

Cash Return on Invested Capital (CROIC) of Beigene changed from -15.47 % to 17.93 %, representing a -215.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Beigene since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Beigene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Beigene

All Key Metrics — Beigene